nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A case report of pegcetacoplan use for a pregnant woman with paroxysmal nocturnal hemoglobinuria
|
Du, Wei |
|
|
8 |
4 |
p. |
artikel |
2 |
Activated protein C resistance in the copresence of emicizumab and activated prothrombin complex concentrates
|
Nakajima, Yuto |
|
|
8 |
4 |
p. |
artikel |
3 |
An epidemiologic study comparing cancer- and noncancer-associated venous thromboembolism in a racially diverse Southeastern United States county
|
Peseski, Andrew M. |
|
|
8 |
4 |
p. |
artikel |
4 |
A real-time prognostic model for venous thromboembolic events among hospitalized adults
|
Tillman, Benjamin F. |
|
|
8 |
4 |
p. |
artikel |
5 |
Artificial intelligence–assisted ultrasound imaging in hemophilia: research, development, and evaluation of hemarthrosis and synovitis detection
|
Nagao, Azusa |
|
|
8 |
4 |
p. |
artikel |
6 |
A small-molecule hemostatic agent for the reversal of direct oral anticoagulant–induced bleeding
|
Desvages, Maximilien |
|
|
8 |
4 |
p. |
artikel |
7 |
Authors’ response to “Venous Thromboembolism Risk Models in Hospitalized Medical Patients: The Time for Implementation, Not Never-Ending Development”
|
Zakai, Neil A. |
|
|
8 |
4 |
p. |
artikel |
8 |
Bleeding risk from anticoagulant thromboprophylaxis in patients with multiple myeloma: a MarketScan analysis
|
Adrianzen-Herrera, Diego |
|
|
8 |
4 |
p. |
artikel |
9 |
Challenging the current hypothesis that thrombosis is responsible for the post-COVID-19 condition
|
Hunt, Beverley J. |
|
|
8 |
4 |
p. |
artikel |
10 |
Clinical phenotype and laboratory characteristics of 93 patients with congenital fibrinogen disorders from unrelated 36 families
|
Tian, Dandan |
|
|
8 |
4 |
p. |
artikel |
11 |
Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study
|
Tran, Huyen |
|
|
8 |
4 |
p. |
artikel |
12 |
Direct oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use
|
Khairani, Candrika D. |
|
|
8 |
4 |
p. |
artikel |
13 |
Disease severity drives risk of venous thrombotic events in women with sickle cell disease in a single-center retrospective study
|
Light, Jennifer |
|
|
8 |
4 |
p. |
artikel |
14 |
Do we need to treat asymptomatic catheter-related thrombosis?
|
Debourdeau, Philippe |
|
|
8 |
4 |
p. |
artikel |
15 |
Earlier onset of acute venous thromboembolism with upadacitinib compared with tofacitinib during Janus kinase inhibitor therapy
|
Lowell, Jeffrey A. |
|
|
8 |
4 |
p. |
artikel |
16 |
Editorial Board
|
|
|
|
8 |
4 |
p. |
artikel |
17 |
Electronic alerts to improve management of heparin-induced thrombocytopenia
|
Zon, Rebecca L. |
|
|
8 |
4 |
p. |
artikel |
18 |
Emicizumab as first-line therapy in acquired hemophilia A
|
Iarossi, Michael |
|
|
8 |
4 |
p. |
artikel |
19 |
Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review
|
Young, Guy |
|
|
8 |
4 |
p. |
artikel |
20 |
Evaluation of an automated von Willebrand factor glycoprotein IbM activity assay compared with 3 alternative von Willebrand factor activity assays
|
Friedman, Kenneth D. |
|
|
8 |
4 |
p. |
artikel |
21 |
Evaluation of thrombomodulin/thrombin activatable fibrinolysis inhibitor function in plasma using tissue-type plasminogen activator-induced plasma clot lysis time
|
Urano, Tetsumei |
|
|
8 |
4 |
p. |
artikel |
22 |
Exploring nonreplacement therapies’ impact on hemophilia and other rare bleeding disorders
|
Peyvandi, Flora |
|
|
8 |
4 |
p. |
artikel |
23 |
Feasibility and acceptability of patient- and clinician-level antithrombotic stewardship interventions to reduce gastrointestinal bleeding risk in patients using warfarin (Anticoagulation with Enhanced Gastrointestinal Safety): a factorial randomized controlled pilot trial
|
Kurlander, Jacob E. |
|
|
8 |
4 |
p. |
artikel |
24 |
Functional limitations 3 and 12 months after venous thromboembolism: a cohort study
|
Steiner, Daniel |
|
|
8 |
4 |
p. |
artikel |
25 |
Heavy menstrual bleeding on direct factor Xa inhibitors: the MEDEA randomized clinical trial
|
Hamulyák, Eva N. |
|
|
8 |
4 |
p. |
artikel |
26 |
Heparin-induced thrombocytopenia after cardiac surgery. A single-center, retrospective cohort study
|
Bevilacqua, Sergio |
|
|
8 |
4 |
p. |
artikel |
27 |
High levels of anti–factor VIII immunoglobulin G4 and immunoglobulin G total are associated with immune tolerance induction failure in people with congenital hemophilia A and high-responding inhibitors
|
Chaves, Daniel Gonçalves |
|
|
8 |
4 |
p. |
artikel |
28 |
Highly thrombogenic phenotype and impaired wound healing in a patient with congenital dysfibrinogenemia: case report
|
El Beayni, Nancy |
|
|
8 |
4 |
p. |
artikel |
29 |
High-risk subgroups were not identified to benefit from thromboprophylaxis after hospitalization for COVID-19
|
Baumann Kreuziger, Lisa |
|
|
8 |
4 |
p. |
artikel |
30 |
Hyperfibrinolysis during the treatment of rhabdomyosarcoma
|
Taylor, Samuel R. |
|
|
8 |
4 |
p. |
artikel |
31 |
Hypocoagulability in severe yellow fever infection is associated with bleeding: results from a cohort study
|
Jardim, Leticia Lemos |
|
|
8 |
4 |
p. |
artikel |
32 |
Identification of heparin interaction sites on thrombin-activatable fibrinolysis inhibitor that modulate plasmin-mediated activation, thermal stability, and antifibrinolytic potential
|
Marar, Tanya T. |
|
|
8 |
4 |
p. |
artikel |
33 |
Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress
|
Ward, Chris |
|
|
8 |
4 |
p. |
artikel |
34 |
Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)
|
Fischer, Kathelijn |
|
|
8 |
4 |
p. |
artikel |
35 |
Issue Information
|
|
|
|
8 |
4 |
p. |
artikel |
36 |
Learnings from the United Kingdom infected blood inquiry
|
Makris, Michael |
|
|
8 |
4 |
p. |
artikel |
37 |
Letter to Dobesh et al. on lower mortality with andexanet alfa in factor Xa inhibitor–related major bleeding
|
Lucarelli, Stefani |
|
|
8 |
4 |
p. |
artikel |
38 |
Mitral regurgitation is associated with similar loss of von Willebrand factor large multimers but lower frequency of anemia compared with aortic stenosis
|
Takiguchi, Hiroshi |
|
|
8 |
4 |
p. |
artikel |
39 |
Obstetric antiphospholipid syndrome carries an increased lifetime risk for obstetric and thrombotic complications—a population-based study
|
Rhein, Ariel Katherine |
|
|
8 |
4 |
p. |
artikel |
40 |
Outcomes of direct oral anticoagulants with aspirin vs warfarin with aspirin: a registry-based cohort study
|
Schaefer, Jordan K. |
|
|
8 |
4 |
p. |
artikel |
41 |
Performance of risk scores in predicting major bleeding in left ventricular assist device recipients: a comparative external validation
|
van der Horst, S.F.B. |
|
|
8 |
4 |
p. |
artikel |
42 |
Perioperative management and neuraxial analgesia in women with factor XI deficiency (<60 IU/dL): a French multicenter observational study of 314 pregnancies
|
Flaujac, C. |
|
|
8 |
4 |
p. |
artikel |
43 |
Psychometrics of patient-reported outcomes measurement information system in von Willebrand disease, inherited platelet function disorders, and rare bleeding disorders
|
van Hoorn, Evelien S. |
|
|
8 |
4 |
p. |
artikel |
44 |
Rare inherited coagulation disorders: no longer orphan and neglected
|
Mohsenian, Samin |
|
|
8 |
4 |
p. |
artikel |
45 |
Reply to “Letter to Dobesh et al. on lower mortality with andexanet alfa in factor Xa inhibitor–related major bleeding”
|
Dobesh, Paul P. |
|
|
8 |
4 |
p. |
artikel |
46 |
Safety and efficacy of danazol in immune thrombocytopenia: a systematic review
|
Shah, Sangam |
|
|
8 |
4 |
p. |
artikel |
47 |
Salvianolic acid B inhibits thrombosis and directly blocks the thrombin catalytic site
|
Neves, Miguel A.D. |
|
|
8 |
4 |
p. |
artikel |
48 |
Starving in the land of plenty: the challenge of studying menstruation in anticoagulated patients
|
Samuelson Bannow, Bethany T. |
|
|
8 |
4 |
p. |
artikel |
49 |
Targeted exome analysis in patients with rare bleeding disorders: data from the Rare Bleeding Disorders in the Netherlands study
|
Willems, Sterre P.E. |
|
|
8 |
4 |
p. |
artikel |
50 |
The fatty liver index and risk of incident venous thromboembolism: the Tromsø Study
|
Scheres, Luuk J.J. |
|
|
8 |
4 |
p. |
artikel |
51 |
Thioredoxin-related transmembrane protein 1 negatively regulates coagulation and phosphatidylserine exposure
|
Zhou, Junsong |
|
|
8 |
4 |
p. |
artikel |
52 |
Thromboelastography in acute immunologic reactions: a prospective pilot study
|
Kienbacher, Calvin Lukas |
|
|
8 |
4 |
p. |
artikel |
53 |
Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings
|
Kelly, Richard J. |
|
|
8 |
4 |
p. |
artikel |
54 |
Tutorial: dos and don’ts in clinical prediction research for venous thromboembolism
|
Nemeth, Banne |
|
|
8 |
4 |
p. |
artikel |
55 |
Validation of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) risk scores for venous thromboembolism and bleeding in an independent population
|
Wilkinson, Katherine S. |
|
|
8 |
4 |
p. |
artikel |
56 |
Variant p.Tyr1584Cys: a frequent von Willebrand factor variant in search of von Willebrand disease
|
Seidizadeh, Omid |
|
|
8 |
4 |
p. |
artikel |
57 |
Venous thromboembolism in pregnancy and postpartum: an illustrated review
|
Frank, Annabel K. |
|
|
8 |
4 |
p. |
artikel |
58 |
Venous thromboembolism risk models in hospitalized medical patients: the time for implementation, not never-ending development
|
Spyropoulos, Alex C. |
|
|
8 |
4 |
p. |
artikel |